AVI BioPharma Announces First Quarter 2008 Financial Results Conference Call
May 08 2008 - 9:30AM
Marketwired
PORTLAND, OR today announced that the company will hold a
conference call to report its first quarter 2008 financial results
on Tuesday, May 13, 2008, at 9:30 a.m. Eastern time (6:30 a.m.
Pacific time).
Individuals interested in listening to the live conference call
may do so by dialing 866.507.1212 toll free within the United
States and Canada, or 416.695.7848 for international callers.
Following the conference call, a recording of the call will be
available for download (MP3) on the company's website:
www.avibio.com.
About AVI BioPharma
AVI BioPharma develops therapeutic products for the treatment of
life-threatening diseases using third-generation NeuGene� antisense
drugs and ESPRIT directed RNA alternative splicing technology.
AVI's ESPRIT technology is initially being applied to potential
treatments for Duchenne muscular dystrophy. AVI's NeuGene compounds
are also designed to treat cardiovascular restenosis in stent and
coronary artery bypass graft (CABG) procedures. In addition to
targeting specific genes in the body, AVI's antiviral program uses
NeuGene antisense compounds to combat disease by targeting
single-stranded RNA viruses, including Marburg Musoke and Ebola
Zaire viruses. More information about AVI is available at
www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Press and Investor Contact: Michael Hubbard Email Contact
Director of Corporate Communications (503) 227-0554
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Oct 2023 to Oct 2024